Eiseki Usami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eiseki Usami has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Michio Kimura
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu, Japan
7 shared publicationsTomoaki Yoshimura
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan
7 shared publications- Michio Kimura
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan
6 shared publications Hitomi Teramachi
Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu, Japan
5 shared publicationsHiroki Asano
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu, Japan
4 shared publicationsMina Iwai
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan
4 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by Korean Society of Sleep Medicine in Sleep Medicine Research
- Vol. 16 (4) , 220-225
Factors Contributing to Increased Fall Risk in Patients Administered Orexin Receptor Antagonists
Background and Objective Orexin receptor antagonists (ORAs) are increasingly used as hypnotic sedatives. Compared to γ-aminobutyric acid receptor agonists, ORAs lack muscle-relaxant properties and are associated with a lower risk of falls. However, falls do occur in small numbers. We aimed to determine factors correlated with fall risk in patients administered ORAs.Methods Data of hospitalized patients administered suvorexant or lemborexant between January 1, 2022 and December 31, 2023 were retrospectively analyzed. Patients already taking medications upon hospitalization and those with unknown height or weight were excluded. Falls were identified through incident reports. Propensity-score matching was conducted based on demographics and clinical background, followed by statistical analysis. Logistic regression was applied to factors with p<0.2.Results Of 2,348 patients, 1,324 were eligible for analysis. After propensity-score matching, 66 patients were in the falls group and 132 in the non-falls group. Antidepressant use was significantly more common in the falls group (p=0.017) than in the non-falls group. Antidepressant use was associated with increased fall risk (odds ratio [OR], 14.40; p=0.016), whereas comorbid depression was protective (OR, 0.04; p=0.022). No significant associations were found for lemborexant use, benzodiazepine use, heart failure, or schizophrenia.Conclusions Antidepressants increase fall risk in ORA users, whereas comorbid depression may prevent falls.
- 31 December 2025
- Published by Korean Society of Sleep Medicine in Sleep Medicine Research
- Vol. 16 (4) , 220-225
Open AccessFactors Contributing to Increased Fall Risk in Patients Administered Orexin Receptor Antagonists
Background and Objective Orexin receptor antagonists (ORAs) are increasingly used as hypnotic sedatives. Compared to γ-aminobutyric acid receptor agonists, ORAs lack muscle-relaxant properties and are associated with a lower risk of falls. However, falls do occur in small numbers. We aimed to determine factors correlated with fall risk in patients administered ORAs.Methods Data of hospitalized patients administered suvorexant or lemborexant between January 1, 2022 and December 31, 2023 were retrospectively analyzed. Patients already taking medications upon hospitalization and those with unknown height or weight were excluded. Falls were identified through incident reports. Propensity-score matching was conducted based on demographics and clinical background, followed by statistical analysis. Logistic regression was applied to factors with p<0.2.Results Of 2,348 patients, 1,324 were eligible for analysis. After propensity-score matching, 66 patients were in the falls group and 132 in the non-falls group. Antidepressant use was significantly more common in the falls group (p=0.017) than in the non-falls group. Antidepressant use was associated with increased fall risk (odds ratio [OR], 14.40; p=0.016), whereas comorbid depression was protective (OR, 0.04; p=0.022). No significant associations were found for lemborexant use, benzodiazepine use, heart failure, or schizophrenia.Conclusions Antidepressants increase fall risk in ORA users, whereas comorbid depression may prevent falls.
- 17 October 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt A) , 120496
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database
- 17 October 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt A) , 120496
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database
- 21 May 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (7) , 1352-1360
Comparison of dose rounding and drug vial optimization for reducing anticancer drug waste
Introduction: Numerous injectable anticancer drugs are administered at varying doses based on the body surface area and weight of the patients, often resulting in a certain volume of residual medication. Several anticancer drugs are expensive, thus, their increased use has led to a corresponding increase in drug waste and healthcare costs. Two potential solutions to this issue include drug vial optimization (DVO) and dose rounding (DR). However, DR has rarely been implemented in Japan. Here, we evaluated DVO and DR to assess whether DR could be a viable strategy to reduce the number of anticancer drugs discarded and minimize drug-related costs in Japan. Methods: Patients who received bevacizumab, ramucirumab, gemcitabine, or levofolinate between January and December 2023 at Kanagawa Prefectural Ashigarakami Hospital (Ashigarakami) and Ogaki Municipal Hospital (Ogaki) were included in this study. Actual quantities used for each anticancer drug were extracted from electronic medical records, and the quantities used of drugs during the application of DVO and DR were calculated. Based on these findings, we estimated the reduction in drug waste and the associated cost savings for DVO and DR. Results: DR was more effective than DVO in minimizing the waste of drugs, with 0% waste for gemcitabine at Ogaki and 0% waste for levofolinate at both institutions. Conclusion: Compared with DVO, DR is not influenced by the number of patients treated or the volume of anticancer drugs administered, making it feasible for implementation across a wide range of institutions and a highly effective strategy for minimizing waste. DR should be advocated as a key approach for reducing drug costs in Japan in the future.
- 21 May 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (7) , 1352-1360
Comparison of dose rounding and drug vial optimization for reducing anticancer drug waste
Introduction: Numerous injectable anticancer drugs are administered at varying doses based on the body surface area and weight of the patients, often resulting in a certain volume of residual medication. Several anticancer drugs are expensive, thus, their increased use has led to a corresponding increase in drug waste and healthcare costs. Two potential solutions to this issue include drug vial optimization (DVO) and dose rounding (DR). However, DR has rarely been implemented in Japan. Here, we evaluated DVO and DR to assess whether DR could be a viable strategy to reduce the number of anticancer drugs discarded and minimize drug-related costs in Japan. Methods: Patients who received bevacizumab, ramucirumab, gemcitabine, or levofolinate between January and December 2023 at Kanagawa Prefectural Ashigarakami Hospital (Ashigarakami) and Ogaki Municipal Hospital (Ogaki) were included in this study. Actual quantities used for each anticancer drug were extracted from electronic medical records, and the quantities used of drugs during the application of DVO and DR were calculated. Based on these findings, we estimated the reduction in drug waste and the associated cost savings for DVO and DR. Results: DR was more effective than DVO in minimizing the waste of drugs, with 0% waste for gemcitabine at Ogaki and 0% waste for levofolinate at both institutions. Conclusion: Compared with DVO, DR is not influenced by the number of patients treated or the volume of anticancer drugs administered, making it feasible for implementation across a wide range of institutions and a highly effective strategy for minimizing waste. DR should be advocated as a key approach for reducing drug costs in Japan in the future.
- 1 February 2025
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 41 (2) , 75-85
Efficiently Reducing Medical Costs through Drug Vial Optimization and Multidose Vials for the Utilization of Cancer Drug Compounding Robots
- 1 February 2025
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 41 (2) , 75-85
Efficiently Reducing Medical Costs through Drug Vial Optimization and Multidose Vials for the Utilization of Cancer Drug Compounding Robots
- 23 September 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (1) , 24-31
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma
Introduction: Lenvatinib (LEN) is the standard treatment for hepatocellular carcinoma (HCC). In clinical practice, gastrointestinal (GI) symptoms such as fatigue and loss of appetite often lead to dose reduction or treatment discontinuation. This study aimed to identify the predictors of patients who will experience dose reduction or treatment discontinuation owing to fatigue or GI symptoms during LEN treatment for HCC. Methods: We retrospectively identified 99 patients who received LEN at the Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and December 2023. To investigate the risk factors for treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration, patients were divided into two groups based on whether treatment discontinuation or dose reduction occurred due to fatigue or GI symptoms during LEN administration (37 patients) or not (62 patients). We compared baseline characteristics between the two groups. Results: Multivariate analysis revealed that body weight (odds ratio 4.310, 95% confidence interval 1.380–13.500; P = 0.002) was an independent risk factor that significantly contributed to treatment discontinuation or dose reduction owing to fatigue or GI symptoms during LEN administration. The cut-off value calculated using the body weight curve was 55.0 kg. Using this cutoff value, the sensitivity and specificity of body weight to detect treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration were 83.9% and 56.8%, respectively. Conclusion: In clinical practice, patients weighing less than 55 kg who start with a full dose will likely experience weight loss or discontinuation during treatment.
- 23 September 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 32 (1) , 24-31
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma
Introduction: Lenvatinib (LEN) is the standard treatment for hepatocellular carcinoma (HCC). In clinical practice, gastrointestinal (GI) symptoms such as fatigue and loss of appetite often lead to dose reduction or treatment discontinuation. This study aimed to identify the predictors of patients who will experience dose reduction or treatment discontinuation owing to fatigue or GI symptoms during LEN treatment for HCC. Methods: We retrospectively identified 99 patients who received LEN at the Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and December 2023. To investigate the risk factors for treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration, patients were divided into two groups based on whether treatment discontinuation or dose reduction occurred due to fatigue or GI symptoms during LEN administration (37 patients) or not (62 patients). We compared baseline characteristics between the two groups. Results: Multivariate analysis revealed that body weight (odds ratio 4.310, 95% confidence interval 1.380–13.500; P = 0.002) was an independent risk factor that significantly contributed to treatment discontinuation or dose reduction owing to fatigue or GI symptoms during LEN administration. The cut-off value calculated using the body weight curve was 55.0 kg. Using this cutoff value, the sensitivity and specificity of body weight to detect treatment discontinuation or dose reduction due to fatigue or GI symptoms during LEN administration were 83.9% and 56.8%, respectively. Conclusion: In clinical practice, patients weighing less than 55 kg who start with a full dose will likely experience weight loss or discontinuation during treatment.
- 23 December 2023
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (6) , 670-677
Evaluation of long-term pharmacist-led prospective audit and feedback in antimicrobial stewardship: An 8-year study
- 23 December 2023
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (6) , 670-677
Evaluation of long-term pharmacist-led prospective audit and feedback in antimicrobial stewardship: An 8-year study
- Open Access
Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
Background and Objectives: One type of immune-related adverse event caused by immune checkpoint inhibitors (ICIs) is pituitary-related adverse events. The management of pituitary-related adverse events is important because they can be fatal if not treated promptly. Therefore, this study was conducted to investigate the onset of pituitary-related adverse events using the Japanese Adverse Drug Report (JADER) database. Materials and Methods: Cases registered in the JADER database from 2004 to 2019 were used. The target drugs were ipilimumab, nivolumab, pembrolizumab, avelumab, atezolizumab, and durvalumab, and the target adverse events were the high-level terms “Anterior pituitary hypofunction,” “Anterior pituitary hyperfunction,” “Posterior pituitary disorder,” and “Pituitary neoplasm” in the Medical Dictionary for Regulatory Activities, Japanese version (MedDRA/J). The information component (IC) was used for signal detection and IC delta (ICΔ) was used for women-related signals. Onset timing and patterns were analyzed using the Weibull distribution. Results: Signals were detected with ipilimumab, nivolumab, pembrolizumab, and atezolizumab in “Anterior pituitary hypofunction,” with ICs and 95% credible intervals (95%CrI) of 5.53 (5.30–5.69), 4.96 (4.79–5.08), 4.04 (3.76–4.25), and 2.40 (1.53–3.00). Significant signals were detected in women, except for atezolizumab. Additionally, the time of onset was classified as the wear-out failure type. Inverse signals were detected with ipilimumab and nivolumab in “Posterior pituitary disorder,” with ICs (95%CrI) of −1.24 (−2.80–−0.26), and −0.89 (−1.64–−0.37). Conclusions: Anterior pituitary hypofunction is likely to occur with the long-term administration of ipilimumab, nivolumab, and pembrolizumab. Further investigation is needed to determine the differences in the tendencies to detect signals in the anterior and posterior pituitaries between ipilimumab and nivolumab.
Open AccessPituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
Background and Objectives: One type of immune-related adverse event caused by immune checkpoint inhibitors (ICIs) is pituitary-related adverse events. The management of pituitary-related adverse events is important because they can be fatal if not treated promptly. Therefore, this study was conducted to investigate the onset of pituitary-related adverse events using the Japanese Adverse Drug Report (JADER) database. Materials and Methods: Cases registered in the JADER database from 2004 to 2019 were used. The target drugs were ipilimumab, nivolumab, pembrolizumab, avelumab, atezolizumab, and durvalumab, and the target adverse events were the high-level terms “Anterior pituitary hypofunction,” “Anterior pituitary hyperfunction,” “Posterior pituitary disorder,” and “Pituitary neoplasm” in the Medical Dictionary for Regulatory Activities, Japanese version (MedDRA/J). The information component (IC) was used for signal detection and IC delta (ICΔ) was used for women-related signals. Onset timing and patterns were analyzed using the Weibull distribution. Results: Signals were detected with ipilimumab, nivolumab, pembrolizumab, and atezolizumab in “Anterior pituitary hypofunction,” with ICs and 95% credible intervals (95%CrI) of 5.53 (5.30–5.69), 4.96 (4.79–5.08), 4.04 (3.76–4.25), and 2.40 (1.53–3.00). Significant signals were detected in women, except for atezolizumab. Additionally, the time of onset was classified as the wear-out failure type. Inverse signals were detected with ipilimumab and nivolumab in “Posterior pituitary disorder,” with ICs (95%CrI) of −1.24 (−2.80–−0.26), and −0.89 (−1.64–−0.37). Conclusions: Anterior pituitary hypofunction is likely to occur with the long-term administration of ipilimumab, nivolumab, and pembrolizumab. Further investigation is needed to determine the differences in the tendencies to detect signals in the anterior and posterior pituitaries between ipilimumab and nivolumab.
- 19 December 2022
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (7) , 1637-1645
Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma
Introduction: We aimed to compare the safety of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh A (CP-A) and Child-Pugh B (CP-B) and to determine the adverse events (AEs) that cause dose reduction/interruption of treatment in patients with CP-B. Methods: Sixty-six patients with lenvatinib as a first-line treatment for HCC at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and January 2022 were retrospectively evaluated. We analyzed the treatment duration, AEs, and reasons for dose reduction/interruption associated with lenvatinib treatment in patients with CP-A and CP-B HCC. Results: The CP-B group had significantly more cases of grade ≥ 2 fatigue and anorexia than the CP-A group ( p = 0.045 and p = 0.042, respectively). Regarding AEs that caused dose reduction/interruption of treatment, the CP-A group had significantly more cases of proteinuria than the CP-B group ( p = 0.015), whereas the CP-B group had significantly more cases of hand-foot syndrome (HFS) than the CP-A group ( p = 0.013). Conclusion: Patients with CP-B have greater difficulty than patients with CP-A in continuing treatment with repeated dose reductions/interruption of treatment due to intolerable grade ≥ 2 AEs (fatigue and anorexia). HFS is more likely to cause dose reduction/interruption of treatment in CP-B than in CP-A unresectable HCC.
- 19 December 2022
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (7) , 1637-1645
Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma
Introduction: We aimed to compare the safety of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh A (CP-A) and Child-Pugh B (CP-B) and to determine the adverse events (AEs) that cause dose reduction/interruption of treatment in patients with CP-B. Methods: Sixty-six patients with lenvatinib as a first-line treatment for HCC at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and January 2022 were retrospectively evaluated. We analyzed the treatment duration, AEs, and reasons for dose reduction/interruption associated with lenvatinib treatment in patients with CP-A and CP-B HCC. Results: The CP-B group had significantly more cases of grade ≥ 2 fatigue and anorexia than the CP-A group ( p = 0.045 and p = 0.042, respectively). Regarding AEs that caused dose reduction/interruption of treatment, the CP-A group had significantly more cases of proteinuria than the CP-B group ( p = 0.015), whereas the CP-B group had significantly more cases of hand-foot syndrome (HFS) than the CP-A group ( p = 0.013). Conclusion: Patients with CP-B have greater difficulty than patients with CP-A in continuing treatment with repeated dose reductions/interruption of treatment due to intolerable grade ≥ 2 AEs (fatigue and anorexia). HFS is more likely to cause dose reduction/interruption of treatment in CP-B than in CP-A unresectable HCC.
- 1 May 2021
- Vol. 76 (5) , 239-242
Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients
We retrospectively evaluated the incidence of skin immune-related adverse effects (irAEs) in patients treated with pembrolizumab (PMB) and explored and the relationship between skin irAEs and PMB efficacy. Thirty-two patients with non-small cell lung cancer treated with PMB between April 2017 and May 2018 were enrolled. The patients were separated into two groups, namely, skin irAEs and no-skin irAEs group. We investigated the ratio and degree of express skin irAEs, period of skin irAEs and treatment, and the PFS between the two groups. Additionally, we evaluated the PFS between the irAE and no-irAEs groups. The median patient age was 76.5 (range 56-92) years. The European Cooperative Oncology Group Performance Status (ECOG PS) score of 26, 5, and 1 was 0-1, 2, and 3, respectively. The male/female ratio was 23/9. In terms of clinical stages, 6, 21, and 5 patients were in stages III and IV, and postoperative relapse, respectively. Skin irAEs were observed in 10 patients (31%). The progression-free survival of patients with skin irAEs (median, 390 days) was longer than that of patients without skin irAEs (median, 128.5 days). Overall, we suggested a significant association between skin irAEs and the efficacy of PMB in treating non-small cell lung cancer. As skin irAEs can be an indicator of treatment efficacy, it is important for medical staff, including pharmacists, to closely observe these adverse events.
- 1 May 2021
- Vol. 76 (5) , 239-242
Association between immune-related dermatologic adverse events and efficacy of pembrolizumab in non-small cell lung cancer patients
We retrospectively evaluated the incidence of skin immune-related adverse effects (irAEs) in patients treated with pembrolizumab (PMB) and explored and the relationship between skin irAEs and PMB efficacy. Thirty-two patients with non-small cell lung cancer treated with PMB between April 2017 and May 2018 were enrolled. The patients were separated into two groups, namely, skin irAEs and no-skin irAEs group. We investigated the ratio and degree of express skin irAEs, period of skin irAEs and treatment, and the PFS between the two groups. Additionally, we evaluated the PFS between the irAE and no-irAEs groups. The median patient age was 76.5 (range 56-92) years. The European Cooperative Oncology Group Performance Status (ECOG PS) score of 26, 5, and 1 was 0-1, 2, and 3, respectively. The male/female ratio was 23/9. In terms of clinical stages, 6, 21, and 5 patients were in stages III and IV, and postoperative relapse, respectively. Skin irAEs were observed in 10 patients (31%). The progression-free survival of patients with skin irAEs (median, 390 days) was longer than that of patients without skin irAEs (median, 128.5 days). Overall, we suggested a significant association between skin irAEs and the efficacy of PMB in treating non-small cell lung cancer. As skin irAEs can be an indicator of treatment efficacy, it is important for medical staff, including pharmacists, to closely observe these adverse events.
- 1 April 2020
- Vol. 75 (4) , 154-158
Continuity and efficacy of real-world use of azacitidine
Long-term azacitidine (AZA) treatment is necessary for its maximal therapeutic effect. This study examined the continuity and efficacy of AZA treatment in real-world use. We conducted a retrospective study in 38 patients who had completed AZA treatment at the Ogaki Municipal Hospital between April 2011 and August 2019. The median number of AZA received cycles was 4. The number of AZA treatment cycles received was 1-3 cycles in 15 (39.5%), 4-6 cycles in 15 (39.5%), and >= 7 cycles in 8 (21.1%). The most common reason for discontinued AZA treatment was infection. Overall response rate was 33.3% in patients with discontinued AZA use (< 4 cycles) and 56.5% in patients with continued AZA (>= 4). Median overall survival (OS) was 124 (15-529) days and 391 (132-2,825) days in the respective groups (p<0.01). The presence of peripheral blood blasts (PBs) was a prognostic factor for continuation of treatment (p=0.03). Discontinued AZA treatment due to infection (p<0.01), and PBs (p=0.03) were unfavourable prognostic factors for OS. Long-term AZA use is beneficial for improvement and survival. Infection control and presence of PBs were important factors for continuing AZA. These data support the idea of long-term continued treatment with AZA for optimal benefit to patients.
- 1 April 2020
- Vol. 75 (4) , 154-158
Continuity and efficacy of real-world use of azacitidine
Long-term azacitidine (AZA) treatment is necessary for its maximal therapeutic effect. This study examined the continuity and efficacy of AZA treatment in real-world use. We conducted a retrospective study in 38 patients who had completed AZA treatment at the Ogaki Municipal Hospital between April 2011 and August 2019. The median number of AZA received cycles was 4. The number of AZA treatment cycles received was 1-3 cycles in 15 (39.5%), 4-6 cycles in 15 (39.5%), and >= 7 cycles in 8 (21.1%). The most common reason for discontinued AZA treatment was infection. Overall response rate was 33.3% in patients with discontinued AZA use (< 4 cycles) and 56.5% in patients with continued AZA (>= 4). Median overall survival (OS) was 124 (15-529) days and 391 (132-2,825) days in the respective groups (p<0.01). The presence of peripheral blood blasts (PBs) was a prognostic factor for continuation of treatment (p=0.03). Discontinued AZA treatment due to infection (p<0.01), and PBs (p=0.03) were unfavourable prognostic factors for OS. Long-term AZA use is beneficial for improvement and survival. Infection control and presence of PBs were important factors for continuing AZA. These data support the idea of long-term continued treatment with AZA for optimal benefit to patients.